Abstract Bladder cancer is the fifth most common type of cancer in the USA, with over 70,000 new cases diagnosed each year. Treatment often involves invasive surgical therapies, as chemotherapy alone is often ineffective and associated with high recurrence rates. Identification of estrogen receptor-β (ERβ) in up to 75 % of urinary tumors raises the question of whether this receptor could be targeted to effectively treat bladder cancer. In this study, a panel of five bladder cancer cell lines representing a variety of disease stage and grades were treated with the antiestrogens 4-hydroxytamoxifen, raloxifene, or the pure antagonist ICI 182,780. All cell lines were ERβ positive while only a few expressed estrogen receptor-α (ERα). Notably, all but the TCCSUP cell line were growth inhibited 20-100 % by at least two antiestrogens. Using RT4 cells, we demonstrate that growth inhibition by raloxifene is ER dependent and either ERα or ERβ can mediate this response. Activation of caspase-3 and its effector poly-ADP ribose polymerase (PARP) demonstrate that raloxifene-induced growth inhibition is in part the result of increased apoptosis; this PARP cleavage was ER dependent. Moreover, changes in the expression of cell cycle genes indicate that cell proliferation is also affected. Specifically, raloxifene treatment results in the stabilization of p27 protein, likely via the downregulation of S-phase kinase-associated protein (SKP2). Expression of the negative cell cycle regulator B-cell translocation gene (BTG2) is also increased, while cyclin D1 transcription is reduced. These results indicate that antiestrogens may be useful therapeutics in the treatment of bladder cancer by targeting ER and inhibiting growth via multiple mechanisms.
Introduction
Bladder cancer is the fifth most common type of cancer in the USA, with over 70,000 new diagnoses reported annually [1] . Nearly 90 % of these cases are urothelial cell carcinomas (UCC) which arise in the epithelial lining of the bladder wall. Despite established treatments like transurethral resection and intravesical therapy, recurrences are frequent and range from 30 to 80 %, depending on initial tumor stage and grade [2, 3] . This high recurrence rate coupled with extensive follow-up care makes bladder cancer the most expensive malignancy from diagnosis until death [4] ; hence, there is an urgent need to develop new effective therapies for this disease.
The estrogen receptors ERα and ERβ are transcription factors that modulate diverse cellular processes such as proliferation, differentiation, and apoptosis [5] . Encoded by unique genes, these receptors are structurally similar with each containing an N-terminal activation function (AF)-1 and a ligand-dependent AF-2 located near the C terminus. In ERα, the AF-1 and AF-2 function independently but can synergize to produce maximal transcriptional activity [6] . Conversely, the AF-1 of ERβ contains a repression domain that suppresses transcription responses [7] .
These differences are thought to contribute to the receptors' oft opposing functional outcomes. While ERα can promote the proliferation of breast epithelial and other cell types, the effects of ERβ are markedly antiproliferative and proapoptotic [7, 8] . The latter receptor additionally regulates cell motility, negatively impacting invasion and promoting cell adhesion [8] . In spite of these antitumor-like activities, expression of ERβ does not always correlate with improved disease outcomes. For instance, in non-small cell lung cancer, high levels of ERβ predict reduced survival in patients with advanced disease [9] . Moreover, estrogen-stimulated proliferation of these cells is ERβ dependent [10] . Thus, like ERα, ERβ can also mediate proliferation, albeit in a cell typespecific manner.
Normal bladder urothelium predominantly expresses ERβ, and this receptor is found in up to 75 % of UCCs [11] [12] [13] . Interestingly, ERβ is more often detected in tumors of advanced stage and grade [11, 12] , though high levels of ERβ expression in noninvasive, low-grade tumors predict better recurrence-free survival [14] . In contrast, ERα has been reported in less than 30 % of UCC samples [11, 12, 15] . Given the prevalence of ERα and ERβ in UCC and their ability to impact proliferation in other cells types, it was hypothesized that these receptors represent novel targets for the treatment of bladder cancer.
Antiestrogens such as the selective estrogen receptor modulator (SERM) tamoxifen are currently used clinically to treat ERα-positive breast cancers. These compounds compete with the receptors' cognate ligands to antagonize activity. Yet, despite their ability to bind to ERs, antiestrogen effects, namely inhibition of proliferation and induction of apoptosis, can occur through both ER-dependent and ERindependent means [16, 17] . For example, tamoxifen produces a G1 arrest in breast cancer cells through the ERmediated downregulation of cyclin D1, but this drug can also inhibit the proliferation of a number of ER-negative malignancies via the modulation of mitogen-activated protein kinase and protein kinase C signaling cascades [18] [19] [20] [21] . Moreover, antiestrogens do not require ER to stimulate caspase-dependent apoptosis at high doses [22] . Therefore, many cell types with varying levels of ER expression may be responsive to antiestrogen treatment.
Early reports exploring the use of SERMs in bladder cancer showed that tamoxifen enhanced UCC sensitivity to standard chemotherapeutics in vitro [23] , while a more recent study found that tamoxifen and raloxifene (Ral) could inhibit the growth of the invasive UCC cell line 5637 [24] . These reports did not examine the ER dependency of these responses nor was the mechanism of antiestrogen action determined. In the present study, we screened a panel of UCC cell lines for ER expression and examined whether tamoxifen, Ral, or the pure antiestrogen ICI 182,780 (ICI) could inhibit their growth. As the majority of bladder cancers are diagnosed as low grade, noninvasive tumors [1, 25] , the representative cell line RT4 was used to further characterize the antiestrogen response, including its dependency on ER and its ability to affect apoptosis and cell cycle progression.
Materials and Methods

Cell Lines and Culturing Conditions
The 5637, MCF-7, PC-3, RT4, T24, and TCCSUP cell lines were obtained from the American Type Culture Collection (ATCC) and cultured according to ATCC recommended conditions for each cell line. TSU-Pr1 cells, a gift from Dr. Tim Thompson [12] , were cultured in RPMI media containing 10 % fetal bovine serum (FBS). The UM-UC-9 and UM-UC-14 cell lines were generous gifts from Dr. David McConkey (University of Texas-MD Anderson Cancer Center) and were cultured in minimum essential media (MEM) containing 10 % FBS, 2 % MEM vitamins, 1 % sodium pyruvate, and 1 % nonessential amino acids. The SVHUC line was a kind gift from Dr. J.T. Hsieh (University of Texas-Southwestern) and was cultured in T-medium with 5 % FBS. For all experiments, cells were plated in growth media containing 10 % FBS to improve adherence. The following day, cells were washed with phosphate-buffered saline (PBS), and unless otherwise indicated, experiments were carried out in phenol red-free Dulbecco's modified Eagle's media (DMEM) containing 1 % charcoal-stripped FBS (sFBS) and 1X GlutaMAX I (Invitrogen).
ER Ligands
The ER ligands 17β-estradiol (E2), 4-hydroxytamoxifen (4HT), and Ral were obtained from Sigma Aldrich. ICI 182,780 was purchased from Tocris.
Cell Proliferation Assays
For 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) proliferation assays, cells were plated at low density and ligands applied the following day in growth media containing 1 % sFBS. Six days later, CellTiter 96 AQueous One Solution (Promega) was added according to manufacturer's instructions. Cells were incubated for 2 h at 37°C, and absorbance was measured at 450 nm. Cell counts were determined for RT4 and TSU-Pr1 cells treated with ligand at the indicated concentrations in growth media containing 1 % sFBS. Cells were incubated for 8 days, with fresh media applied on days 4 and 6. On day 8, cells were harvested and counted using a Beckman Coulter Z1 Particle Counter. For cell number determinations by crystal violet, cells were plated as noted above and incubated for 24 h in DMEM prior to ligand addition. Following ligand treatment and culture for 1-5 days, cells were washed with PBS, incubated with a solution of 1 % crystal violet (w/v) in 10 % ethanol for 10 min at RT, and then extensively washed with PBS. Plates were dried, and stain was subsequently solubilized in 10 % acetic acid. Absorbance was determined at 595 nm. Assays to determine 3 H-thymidine incorporation were carried out in parallel with crystal violet assays. RT4 cells were treated with ligand for 18 h at which time 3 H-thymidine was added. Six hours later (24 h total ligand exposure), cells were fixed in a 3:1 solution of methanol and acetic acid. Excess 3 Hthymidine was removed with 5 % trichloracetic acid, and cells were lysed in 1 N NaOH. Lysates were neutralized in Biodegradable Counting Scintillant (Amersham) containing HCl, and radioactivity was counted using a Beckman LS 6500 Scintillation Counter (Beckman).
RT-qPCR
Total RNA was extracted with TRIzol (Invitrogen) according to the manufacturer's recommendations. First-strand cDNA synthesis was carried out using qScript cDNA SuperMix (Quanta) and subsequent real time PCR was performed in an ABI 7500 Real-Time PCR System using low ROX forms of PerfeCTA SYBR Green FastMix or PerfeCTA FastMix II (both from Quanta) for SYBR Green or Taqman probe detection, respectively. Following manufacturer's instructions, qPCR reactions containing cDNA, FastMix, and primers or primers/probe were denatured at 95°C for 1 min and then cycled according to a two-step protocol for 40 cycles (5 s at 95°C and 45 s at 60°C). Target gene expression was calculated using the ΔΔCt method and normalized to levels of 18S RNA. SYBR Green was used to detect amplification using previously reported primers of ERα [12] , ERβ [12] , and cyclin D1 [26] cDNAs. Taqman gene expression assays (Applied Biosystems) with premixed primer/probe were used to detect amplification of B-cell translocation gene 2 (BTG2), p27, and S-phase kinase-associated protein 2 (SKP2) cDNAs. Taqman chemistry also was used to quantify levels of 18S RNA (Applied Biosystems).
Western Blotting
For detection of ERα, ERβ, and p27, western blotting was carried out as previously described [27] . For efficient recovery of poly-ADP ribose polymerase (PARP) and caspase-3, cells were collected in TEN buffer (40 mM Tris, pH 8, 1 mM EDTA, and 150 mM NaCl), resuspended in PARP extraction buffer (62.5 mM Tris, pH 6.8, 6 M Urea, 10 % glycerol, 2 % SDS, 0.003 % bromophenol blue, and 5 % 2-mercaptoethanol) and sonicated for 1 min at maximum amplitude in an S-4000 Bath Ultrasonic Liquid Processor (Misonix). Samples were stored overnight at −80°C and then heated to 75°C for 15 min. Protein separation was carried out on equivolume samples, and blotting continued as described above. Primary antibodies used include ERα (HC-20; Santa Cruz), ERβ (H-150; Santa Cruz), p27 (C-19; Santa Cruz), PARP (Anti-PARP; Roche), caspase-3 (3G2; Cell Signaling), actin (Clone C4; Millipore), and β-tubulin (Clone AA2; Millipore).
RNA Interference
RT4 cells were transfected with 50 pmol siGENOME SMARTpool siRNA (Dharmacon-nontargeting siRNA #3, D001210-03; ESR1, M-003401-04; or ESR2, M-003402-04) using Lipofectamine RNAiMAX (Invitrogen) for each well of a six-well multiplate. Following overnight incubation, medium was replaced with DMEM containing 1 % sFBS, 1× GlutaMAX I, and ligand treatments.
Cell Death ELISA RT4 cells were treated with Ral and/or the caspase inhibitor Z-VAD-FMK (Promega) in growth media containing 5 % FBS and harvested 24 h later. Apoptosis was determined using a colorimetric Cell Death Detection ELISA kit (Roche), following the manufacturer's instructions.
Results
The extent to which antiestrogens inhibit the growth of bladder cancer cells was tested in five UCC cell lines representing non-muscle invasive, invasive, and metastatic disease. Proliferation was determined by MTS assay following 6 days of ligand treatment. As expected, 5637 cells, which were previously shown to be growth inhibited by 4HT [24] , exhibited reduced proliferation in the presence of this ligand as well as the pure antiestrogen ICI (Fig. 1a) . Similarly, a 30-45 % growth inhibition was detected in T24 cells treated with these compounds, while Ral had no effect on either of these cell lines. In contrast, Ral produced the greatest effect in RT4 cells, inhibiting growth by 76 % over vehicle treatment. Exposure to 4HT also limited proliferation of this non-muscle invasive cell line by 47 %. The strongest antiestrogen response occurred in TSU-Pr1 cells, where robust growth inhibition was observed for cells treated with either 4HT or Ral. However, these cells failed to respond to ICI treatment in these MTS assays. Only the metastatic TCCSUP cell line did not respond to any of the ligand treatments, suggesting that the growth inhibitory effects of antiestrogens are widespread across multiple bladder cancer cell lines.
The MTS assay, which infers proliferation from metabolic activity, can conceal growth responses to treatments that alter mitochondrial density or function [28, 29] . Consequently, to confirm the growth inhibitory effect of antiestrogens in bladder cancer cells, a Coulter counter was used to directly determine the number of RT4 cells following ligand treatment (Fig. 1b) . As above, reduced cell numbers for cultures treated with either 4HT or Ral were observed; however, SERM-induced growth inhibition appeared stronger by cell count compared with MTS assay. Additionally, cell counts revealed a significant 54 % decrease in the number of RT4 cells upon ICI treatment. A similar outcome was determined for TSU-Pr1 cells wherein Coulter counter measurements revealed an 85 % decrease in cell number induced by ICI treatment while none was detected by MTS assay. These results suggest that antiestrogens can alter the metabolism of UCC cell lines, which is consistent with the increased mitochondrial activity observed in ICI-treated MCF-7 cells [29] and indicates that the MTS assay underestimates the capacity of antiestrogens to inhibit UCC growth.
Antiestrogens exert their effects in part by competing with cognate ligands to bind and disrupt ER function. To assess ER expression in cell models of bladder cancer, seven UCC cell lines were screened for both ERα and ERβ mRNA expression. These included 5637, RT4, T24, TCCSUP, TSU-Pr1, UM-UC-9, and UM-UC-14 cells. Data indicate that compared with ERα-positive MCF-7 breast cancer cells, only 5637 and RT4 cells were positive for ERα transcript, with levels~1 % of those detected for MCF-7 cells (Fig. 2a) . Low levels of ERα mRNA were also detected for SVHUC, a normal urothelial cell line immortalized by large T antigen. In contrast, compared with the ERβ-positive PC-3 prostate cancer cell line [30, 31] , ERβ transcript was found in all UCC cell lines tested as well as the nonmalignant SVHUC cells (Fig. 2c) . These results indicate that most bladder cancer cell lines primarily express ERβ while few are positive for ERα-findings analogous to ER expression patterns in human tumors, particularly those with increased tumor stage and grade [11, 12] . Notably, TCCSUP cells, which did not respond to antiestrogen treatment, expressed some of the lowest levels of ERβ mRNA.
Although a considerable number of cell models exist for advanced bladder cancer, the majority of UCCs are diagnosed as low grade, non-muscle invasive tumors [1, 25] . Recent genetic analyses identified RT4 as a clinically relevant UCC cell line, representative of low grade, non-muscle invasive disease [32] . Moreover, the RT4 gene expression profile correlates with long-term patient survivorship, a hallmark of low grade urothelial carcinomas [32, 33] . Consequently, we decided to use this cell line as a representative model of bladder cancer to explore the mechanism of the (Fig. 2b) . In contrast, ERβ protein was readily detected, with levels even greater than those of the ERβ-positive control PC-3 (Fig. 2d) . Thus, like many bladder tumors, RT4 cells predominantly express ERβ. However, identification of ERα and ERβ protein in this cell line provided an opportunity to assess whether both receptors could contribute to the UCC antiestrogen response.
To determine if antiestrogen-induced growth inhibition of bladder cancer cells was ER dependent, RT4 cells were transiently transfected with ER-targeted siRNA and subsequently treated with Ral. Since RT4 cells express both estrogen receptors, ER dependency was first established by removing ERα and ERβ simultaneously. Analysis of receptor expression following RNA interference indicated a 60 % reduction in ERα and ERβ transcripts while receptor proteins were barely detectable (Fig. 3b, c) . Ral treatment in cells transfected with nontargeting control siRNA induced a 70 % reduction in RT4 cell number (Fig. 3a) . However, this response was completely abrogated in cells depleted of ERα and ERβ, indicating that Ral-induced growth inhibition of RT4 cells is ER dependent. Notably, in the absence of ligand, cell proliferation was unperturbed by loss of ER, with cells depleted of ERα and ERβ growing at a rate 1.4± 0.3 times (p00.28) that of cells expressing these receptors. 
in siCtrl-, siERα-, and siERβ-transfected cells, respectively (Fig. 4a) . These data, in combination with that of the ER double knockdown, indicate that both ERα and ERβ have the potential to mediate the antiestrogen response as both must be depleted to block the Ral-induced growth inhibition. Interestingly, examination of expression data revealed that knocking down ERα or ERβ individually resulted in a significant increase in mRNA levels of the opposite receptor (Fig. 4b) . Whether an increase in ERβ expression compensates for loss of ERα, or vice versa, in mediating Ralinduced growth inhibition, or whether Ral effects on RT4 cell growth can be mediated by either estrogen receptor, cannot be resolved at the present time.
Antiestrogen-induced growth inhibition could be the result of an increase in cell death and/or an arrest of cell proliferation [17] . To test whether apoptosis contributed to the antiestrogen response in RT4 cells, a cell death ELISA was used to measure cytoplasmic nucleosomes following Ral administration. Within 24 h of treatment, DNA fragmentation increased over 6-fold, indicative of an early apoptotic event (Fig. 5a) . Use of Z-VAD-FMK, a pan caspase inhibitor, prevented Ral-induced cell death, suggesting that this SERM stimulates apoptosis in bladder cancer cells via a caspase-dependent pathway. Subsequent Western blot analysis confirmed caspase-3 cleavage following 6 h of Ral administration (Fig. 5b) . PARP cleavage, a downstream indicator of caspase activity, also was induced within 6 h of ligand treatment (Fig. 5c) . Moreover, Ral-stimulated PARP cleavage in RT4 cells was blocked by siRNAmediated depletion of ERα and ERβ (Fig. 5d) . Together, these data indicate that Ral-induced growth inhibition of RT4 cells reflects, at least in part, an ER-dependent increase in apoptosis.
The effect of Ral on cell number over time was also evaluated. Consistent with apoptosis induction, observations of RT4 cell growth over a 5-day time course demonstrate that Ral reduces viable cells by 40 % following 24 h of ligand exposure (Fig. 6a) . However, remaining cells proliferate, and within 48 h cell numbers recover to nearly 90 % of the pretreatment value. From 48 to 120 h, the rate of cell growth was reduced for Ral-versus vehicle-treated cultures, suggesting that antiestrogen treatment negatively impacted cell cycle progression. This effect was further assessed by 3 H-thymidine incorporation, which indicated a 60 % reduction in DNA replication in the presence of Ral (Fig. 6b) . In contrast to antiestrogen, treatment with the ER agonist E2 had no effect on DNA replication or 5-day RT4 growth (Fig. 6a, b) , neither stimulating nor inhibiting cell proliferation. The cyclin-dependent kinase inhibitor p27 is a negative regulator of cell cycle progression and a key mediator of the antiproliferation response in tamoxifen-treated MCF-7 cells [34] . Since SERMs can also induce growth inhibition of bladder cancer cells, we evaluated p27 expression in the RT4 line following Ral treatment. Western blots revealed an~2-fold increase in p27 protein 24 h after ligand addition (Fig. 6c) . Importantly, these changes were not accompanied by an increase in p27 mRNA (Fig. 6d) , suggesting the possibility that SERM treatment improved p27 protein stability. Consequently, expression of SKP2, whose ubiquitin ligase activity is required for p27 degradation [35] , was examined. Results indicated a 50 % downregulation of SKP2 mRNA in RT4 cells upon Ral administration. These observations suggest that Ral increases p27 protein expression by reducing the levels of SKP2, thereby enhancing p27 protein stability. Interestingly, SKP2 mRNA was also decreased in E2-treated RT4 cells (Fig. 6d) . However, this reduction was not sufficient to impact p27 protein expression (Fig. 6c) and is therefore consistent with data from the 5-day time course and 3 H-thymidine incorporation assay which demonstrated that E2 had no effect on RT4 cell growth (Fig. 6a, b) .
Lastly, the effects of Ral on the cell cycle regulators cyclin D1 and BTG2 were examined. Normally upregulated during cell proliferation, cyclin D1 promotes the G1 to S phase transition of the cell cycle. Conversely, expression of the tumor suppressor BTG2 induces growth arrest by negatively regulating cyclin D1 transcription [36] . Following Ral treatment, BTG2 mRNA increased by 2-fold in RT4 cells while cyclin D1 expression was reduced by 50 % (Fig. 6e) . These results, coupled with the p27 and SKP2 data above indicate Ral's ability to prevent cell proliferation by altering the expression of cell cycle regulatory genes. Accordingly, Ral-induced growth inhibition of RT4 cells represents a combination of both increased apoptosis and decreased cell cycle progression.
Discussion
Antiestrogens have long been used to treat ERα-positive breast cancers, and their use is currently being investigated in the treatment of other ER-positive malignancies including cancers of the lung, colon and prostate, which, unlike the breast, predominantly express ERβ [37] . The urinary bladder is also an ERβ-positive organ, and expression of this receptor persists in the majority of bladder cancers [11] [12] [13] , thus making ERβ a promising target for novel UCC therapies. Previous reports indicated that the invasive UCC cell line TSU-Pr1 was growth inhibited by Ral in a dosedependent manner, while in vitro studies using 5637 cells showed reduced growth in the presence of Ral or tamoxifen [24, 38] . In this paper, we explored the extent to which these antiestrogens could inhibit the growth of multiple UCC cell lines, representing not just invasive tumors but also cancers of non-muscle invasive and metastatic origin. Furthermore, as Ral and tamoxifen are both SERMs, the growth response of cells treated with the pure antiestrogen ICI was also assessed. With the exception of the metastatic TCCSUP line, all cell lines tested were growth inhibited at least 20 % by two or more antiestrogens. These results suggest that antiestrogen-induced growth inhibition of UCC is widespread and affects cells with a range of tumor stage and grade classifications. While the data herein highlight the negative impact antiestrogens have on UCC growth, they fail to identify a reciprocal, pro-proliferative estrogenic response. Not only was E2 unable to induce RT4 proliferation, but it was unable to alter expression of the cell cycle genes cyclin D1 and BTG2, two direct targets of ERα transcriptional activity identified in breast cancer [27, 39] . Furthermore, although E2 treatment led to a modest reduction in SKP2 expression, this effect was insufficient to impact p27 protein levels. Together these data indicate that the classical E2-ER signaling axis common to breast and other ERα-positive cell types is not active in ERβ-positive bladder cells. A similar effect has been described in ERβ-expressing colon cancer cells, which are not growth stimulated by E2 treatment but are nonetheless growth inhibited by antiestrogens [40] . A recent report suggested that E2 could induce proliferation of the UCC cell line T24, but the authors did not examine changes in cell number over time, instead inferring growth from short-term changes in DNA replication [41] . Moreover, we found that the simultaneous loss of ERα and ERβ did not affect the basal growth rate of RT4 cells, indicating that proliferation of this UCC line occurs independent of ER signaling.
Interestingly, epidemiological reports have identified an apparent association between decreased bladder cancer risk in women and parity, older age at menopause, and increased total years of ovulation [42] [43] [44] indicating that if anything, estrogens may be protective in the development of this disease. However, given that we saw no evidence of this protection in RT4 cells by way of reduced proliferation or increased apoptosis following E2 exposure, the beneficial effect of estrogens on UCC may be limited to preneoplastic tissue. Alternatively, estrogens may exert a protective effect in the bladder via an indirect mechanism. Furthermore, while combination estrogen/progesterone hormone replacement therapy has also been variably linked with reduced UCC risk in women [45] , neither increased nor decreased incidence of bladder cancer has been reported in women using tamoxifen or Ral as a chemopreventive agent for breast cancer [46] [47] [48] . However, the incidence of urinary cancer in these populations is very low, and meaningful conclusions regarding SERMs and bladder carcinogenesis are not possible. Herein initial UCC growth experiments were performed using the MTS assay, a technique that infers proliferation from mitochondrial activity. Results produced by this method may be misleading for compounds that stimulate metabolism but inhibit cell growth. This discordance was previously demonstrated in ICI-treated MCF-7 cells, which exhibit increased mitochondrial respiration despite an arrest of cell cycle progression [29] . According to MTS data, RT4 and TSU-Pr1 cells were growth inhibited by tamoxifen and Ral but not by ICI. However, cell counts indicated that much like SERMs, ICI could also inhibit the growth of these cell lines. Additionally, in RT4 cells 4HT and Ral both showed a stronger inhibition by cell count compared with MTS assay. Although these experiments examined cell growth at different time points-day 6 vs. 8 for MTS and cell count, respectively-the extent of the disparity is larger than would be anticipated based on cell doubling rates. Consequently, the antiestrogen responses reported here by MTS may underestimate the true growth inhibition produced by these compounds and raise the possibility that antiestrogens impact mitochondrial metabolism in bladder cancer. While the role of ERs in any such mitochondrial dysfunction is unknown, both ERα and ERβ have been detected in the mitochondria of certain cell types, including breast and lung cancers [49] [50] [51] .
Antiestrogens can inhibit cell growth through both ERdependent and ER-independent mechanisms [16, 17] . Accordingly, ligand-responsive cell lines were screened for the presence of ERα and ERβ. While only two of seven cell lines were ERα positive, ERβ transcript was detected in all cell lines tested, thus mimicking ER expression profiles seen in primary UCC samples [11] [12] [13] . This analysis indicates that ERα expression is not required for the antiestrogeninduced growth inhibition of all UCC cell lines and suggests that ERβ may be the principal driver of the antiestrogen response in bladder cancer. Nevertheless, using Ral-treated RT4 cells which express both ERα and ERβ, we determined that although antiestrogen-induced growth inhibition is ER dependent, either receptor can mediate this response. Hence, patients with UCC tumors expressing ER of either type may be candidates for antiestrogen treatment.
One way that antiestrogens inhibit cell growth is through the induction of apoptosis. There are two major apoptotic pathways-the extrinsic and the intrinsic pathway-both of which can be triggered by antiestrogen treatment [16, 17] . Although these pathways have different initiating stimuli, they converge at the point of effector caspase activation, specifically the cleavage of caspase-3 [52, 53] . In the present study using RT4 cells, Ral stimulated the cleavage not only of caspase-3 but also its downstream effector PARP. Moreover, PARP cleavage was reduced in Ral-treated cells lacking ERα and ERβ, indicating that antiestrogen-induced apoptosis is ER-dependent. Previously, 5637 cells were shown to be growth inhibited by antiestrogen treatment, but the effect of these compounds on cell death was not examined [12] . In contrast, Kim et al. demonstrated that Ral treatment of TSUPr1 cells led to BAD cleavage and mitochondrial cytochrome c release, but the authors did not test the ER dependency of this response [38] . Thus, to the best of our knowledge this is the first report of antiestrogen-induced, ER-dependent apoptosis of a bladder cancer cell line.
In addition to stimulating an early apoptotic event, Ral also inhibited cell proliferation and altered the expression of cell cycle regulators, including BTG2 and cyclin D1.
Identified as targets of ER transcriptional activity in MCF-7 cells [27, 39] , little is known about the regulation of these genes in cells predominantly expressing ERβ. However, in environments overexpressing ERβ E2-bound receptor can inhibit cyclin D1 expression while unliganded ERβ has been shown to increase expression of BTG2 [54, 55] , actions consistent with this receptor's antiproliferative behavior. Conversely, in primarily ERα-positive cells E2 treatment mediates the downregulation of BTG2 while driving cell cycle progression with cyclin D1 induction [27, 56] . Antiestrogens can inhibit expression of the latter gene, but BTG2 transcription is unaffected by tamoxifen or ICI [27, 57] . In RT4 cells, Ral treatment downregulated cyclin D1 expression yet increased BTG2 transcription by 2-fold. These data coupled with reports from the literature support the cell type-specific regulation of ER target genes, an effect that might be related to levels of ERβ expression and which may or may not be impacted by ligand treatment.
The role of ERs in bladder cancer is currently unknown. However, in other malignancies primarily expressing ERβ, a number of ligand-independent functions for this receptor have been described. For example, in lung cancer unliganded ERβ can bind the proapoptotic protein Bad, preventing its interactions with Bcl-2 and inhibiting apoptosis [50] . Herein we demonstrated that antiestrogens induce cell death in RT4 cells in an ER-dependent manner, indicating that a possible function of ERβ in bladder cancer is to protect cells from apoptosis. Moreover, as E2 had no effect on the proliferation of this cell line, ERβ activity could be ligand-independent similar to that seen in lung cancer cells. Alternatively, antiestrogens may not be inhibiting unliganded ERβ but instead inducing a strictly pharmacological response. This alternate hypothesis is supported by evidence indicating that depletion of ERα and ERβ does not impact RT4 growth. Nevertheless, irrespective of the normal function of ERs in bladder cells, we believe that UCC represents an additional ER-positive cancer that can be targeted with antiestrogens.
